Mapletree is executing well on capital recycling, and risks relating to asset write-offs will be less of a concern going ...
Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock is a Hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback